The impact of influenza on working days lost: A review of the literature

PharmacoEconomics

Volumn 26, Issue 11, 2008, Pages 911-924

  Keech, Martin ^a   Beardsworth, Paul ^b  

^a Pharmakos Ltd   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Indirect costs; Influenza virus infections, assessment; Productivity costs

Indexed keywords

ABSENTEEISM; COST OF ILLNESS; DATA BASE; EPIDEMIC; INFLUENZA; LABORATORY TEST; MEDICAL LEAVE; MEDICAL RESEARCH; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SELF EVALUATION; WORKPLACE;

ABSENTEEISM; ADULT; COST OF ILLNESS; HUMANS; INFLUENZA, HUMAN; SICK LEAVE;

EID: 53849113686     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826110-00004     Document Type: Review

References (87)

1. Couch RB. Influenza: prospects for control. Ann Int Med 2000; 133 (12): 992-8
2. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian J Immunol 2004; 59 (1): 1-15
3. Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004; 64 (18): 2031-46
4. Nguyen-Van-Tam J. Epidemiology of influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 181-206
5. CDC. Key facts about influenza and the influenza vaccine [online]. Available from URL: http:www.cdc.gov/flu/keyfacts.htm [Accessed 2008 Aug 1]
6. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7 (35): 1-170
7. EISS. FAQ Influenza [online]. Available from URL: http://www.eiss.org/ html/faq_influenza.html [Accessed 2008 Aug 1]
8. World Health Organisation. Factsheet Number 211, revised 2003 Mar [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs211/ en/index.html [Accessed 2008 Aug 1]
9. Molinari NAM, Ortega-Sanchez IR, Messonnier ML. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25 (27): 5086-96
10. Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics 2005; 23 (11): 1083-106
11. Anonymous. Economic and social impact of epidemic and pandemic influenza. Vaccine 2006; 24 (44-46): 6776-8
12. Anonymous. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000; 6 (5 Suppl.): S276-81
13. Sessa A, Lucioni C, D'Ambrosio G, et al. Economic evaluation of clinical influenza in Italy. Int J Med 2005; 7 (1): 14-20
14. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44: 11-5
15. Williams JP, Lednar W. New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. AM J Manag Care 2002; 8 (5 Suppl.): S145-56
16. Meier C, Napalkov P, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834-42
17. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283 (8): 1016-24
18. Rhoton-Vlasak A. Viral influenza in women. Primary Care Update Ob Gyns 1999; 6 (1): 1-7
19. Anonymous. Evidence points to influenza vaccination being cost-saving in healthy working adults. Drugs Ther Perspect 2003; 19 (3): 22-5
20. Anonymous. Zanamivir for influenza. Drug Ther Bull 1999; 37 (11): 81-4
21. Fleming DM. The management of influenza in people of working age. Occup Med 2002; 52 (5): 259-63
22. Poland GA, Rottinghaus ST, Jacobson RM. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001; 19 (17-19): 2216-20
23. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 1998; 10 (199): 1-428
24. O'Reilly FW, Stevens AB. Sickness absence due to influenza. Occup Med 2002; 52 (5): 265-9
25. Smith A. The socioeconomic aspects and behavioural effect of influenza. In: Wood C, editor. Influenza: strategies for prevention. London: Royal Society Medicine, 1988: 46-52
26. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1994; 10 (193 Pt 1): 1 -260
27. Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis 2004; 4 (2): 75-83
28. Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? Arch Dis Child 2005; 90 (5): 532-6
29. Block SL. Role of influenza vaccine for healthy children in the US. Paediatr Drugs 2004; 6 (4): 199-209
30. Committee on Infectious Diseases. American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002; 110 (6): 1246-52
31. Heikkinen T, Booy R, Campins M, et al. Should healthy children be vaccinated against influenza? Eur J Pediatr 2006; 165 (4): 223-8
32. Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs 2002; 4 (1): 65-71
33. Gaglani MJ, Herschler GB. Every nose counts: a new influenza vaccine for all healthy schoolchildren? Clin Pediatr 2004; 43 (1): 35-41
34. Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect 2003; 55 (2): 83-91
35. Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27-32
36. Nichol KA, Lind A, Margolis K, et al. The effectiveness of vaccination in healthy, working adults. N Engl J Med 1995; 333 (14): 889-93
37. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database of Syst Rev 2007; (2): CD001269
38. Ahmed AH, Nicholson KG. The efficacy of influenza vaccine. Rev Med Microbiol 1996; 7 (1): 23-30
39. Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine 2001; 19 (31): 4373-7
40. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21 (17-18): 2207-17
41. Olsen GW, Steinberg ME, Ley CA. Worksite influenza immunization programs: insight into the implementation and cost-benefit. AAOHN J 2005; 53 (3): 105-10
42. Szucs TD. Medical economics in the field of influenza: past, present and future. Virus Res 2004; 103 (1-2): 25-30
43. Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Syst Rev 2006; (2): CD001169
44. Hayden FG, Atmar RL, Schilling M, et al. and the Oseltamivir Study Group. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43
45. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
46. Welliver R, Monto AS, Catewicz O, et al. for the Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748-54
47. Hayden FG, Gubareva LV, Monto AS, et al. for the Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282-9
48. Anonymous. Zanamivir and oseltamivir: New options in the management of influenza. Drugs Ther Persp 2000; 15 (6): 1-5
49. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4 (2): 107-16
50. Schwarzinger M, Lacombe K, Carrat F. Economic evaluations of neuraminidase inhibitors to control influenza. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3 (2): 147-58
51. Kumpulainen V, Mäkelä M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29 (2): 181-5
52. Carrat F, Sahler C, Rogez S, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Int Med 2002; 162 (16): 1842-8
53. Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17 (2): 187-95
54. Jacomo V, Sartor C, Zandotti C, et al. Nosocomial influenza outbreak in an intensive-care unit. Med Mal Infect 2001; 31 (9): 563-8
55. Sartor C, Zandotti C, Romain F, et al. Disruption of services in an internal medicine unit due to a nosocomial influenza outbreak. Infect Control Hosp Epidemiol 2002; 23 (10): 615-9
56. Ito Y, Sumi H, Kato T. Evaluation of influenza vaccination in health-care workers, using rapid antigen detection test. J Infect Chemother 2006; 12 (2): 70-2
57. Bosis S, Esposito S, Niesters HGM, et al. Impact of human metapneumovirus in childhood: comparison with respiratory syncytial virus and influenza viruses. J Med Virol 2005; 75: 101-4
58. Esposito S, Gasparini R, Bosis S, et al. Clinical and socioeconomic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clin Microbiol Infect 2005; 11 (11): 933-6
59. Principi N, Esposito S, Gasparini R, et al. Burden of influenza in healthy children and their households. Arch Dis Child 2004; 89 (11): 1002-7
60. Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003; 22 (10 Suppl.): S207-10
61. Carrat F, Schwarzinger M, Housset B, et al. Antibiotic treatment for influenza does not affect resolution of illness, secondary visits or lost workdays. Eur J Epidemiol 2004; 19 (7): 703-5
62. Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults cost-effectiveness of rapid testing and antiviral therapy. J Gen Int Med 2003; 18 (10): 808-15
63. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118 (1): 68-77
64. Das Gupta R, Guest JF. A model to estimate the cost benefit of an occupational vaccination programme for influenza with influvac in the UK. Pharmacoeconomics 2002; 20 (7): 475-84
65. Millot JL, Aymard M, Bardol A. Reduced efficiency of influenza vaccine in prevention of influenza-like illness in working adults: a 7 month prospective survey in EDF Gaz de France employees, in Rhone-Alpes, 1996-1997. Occup Med 2002; 52 (5): 281-92
66. Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001; 18 (6): 629-34
67. Gaillat J, Pecking M, El Sawi A, et al. Neuraminidase inhibitors in the general practice management of influenza: who prescribes them, when and with which results? Med Mal Infect 2005; 35 (9): 435-42
68. Lambert S, O'Grady KA, Gabriel S, et al. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004; 28 (4): 510-6
69. Ng TP, Pwee KH, Niti M, et al. Influenza in Singapore: assessing the burden of illness in the community. Ann Acad Med Singap 2002; 31 (2): 182-8
70. Ramadan PA, de Araujo FB, Ferreira Jr M. A 12-month follow-up of an influenza vaccination campaign based on voluntary adherence: report on upper-respiratory symptoms among volunteers and non-volunteers. Rev Paul Med 2001; 119 (4): 142-5
71. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284 (13): 1655-63
72. Dille JH. A worksite influenza immunization program: impact on lost work days, health care utilization, and health care spending. AAOHN J 1999; 47 (7): 301-9
73. Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ Med 2002; 73 (9): 876-80
74. King Jr JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005; 116 (6): e868-73
75. Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18 (9): 779-83
76. Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work absenteeism. Value Health 2003; 6 (2): 107-15
77. Cohen P, Darling C, Hampson A, et al. Influenza vaccination in an occupational setting: effectiveness and cost-benefit study. J Occup Health Safe Aust NZ 2003; 19 (2): 167-82
78. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156 (10): 986-91
79. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998; 48 (2): 85-90
80. Speroni KG, Dawson E, Atherton M, et al. Influenza vaccination: incidence of symptoms and resulting absenteeism in hospital employees. AAOHN J 2005; 53 (11): 477-83
81. Szucs TD, Ruef C, Muller D, et al. The economic impact of influenza in a university hospital setting. Infect Contr Hosp Epidemiol 2001; 22 (8): 472-4
82. Jefferson T, Wegmuller Y, Barker C, et al. The impact of influenza on the workplace and the effect of the antiviral GS4104 on daily performance and work absenteeism [abstract]. J Antimicrob Chemother 1999; 44 Suppl. A: 46
83. Briner RB. ABC of work related disorders: absence from work. BMJ 1996; 313 (7061): 874-7
84. Smith AP, Thomas M, Brockman P, et al. Effect of influenza B virus infection on human performance. BMJ 1993; 306: 760-1
85. Postma MJ, Jansema P, van Genugten ML, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62 (7): 1013-24
86. Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Jpn J Chemother 2001; 49 (2): 95-102
87. Prosser LA, O'Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmaceoeconomics 2008; 26 (2): 163-78